Equinix Inc (EQIX) Stock Price Today
Aura AI Summary
Key Stats
- $99.77BMarket Cap
- 480,425Volume
- Real EstateSector
- $1.12K52W High
- $726.0952W Low
- 110 DaysTypical Hold Time
- $120.90BEnterprise Value
- 2.04%Div Yield
- -Trading Activity
Track Equinix Inc (EQIX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Equinix Inc has traded between a low of $726.09 and a high of $1,115.94, highlighting its annual price range. Buy and sell Equinix Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Most Recent News
ZenaTech launches AI-powered smart safety glasses Stacklens for field technicians, with pilots in 2027.
ZenaTech introduced Stacklens™, AI-powered smart safety glasses designed for field technicians and industrial workers, integrating hands-free AI assistance, real-time video support, and thermal imaging. The glasses aim to improve efficiency by allowi...

Class action lawsuit filed over Compass-Anywhere merger alleging regulatory misrepresentation.
The Rosen Law Firm has filed a class action lawsuit on behalf of former Anywhere Real Estate shareholders who received Compass, Inc. stock in a January 2026 merger. The suit alleges that Compass and its executives misrepresented their efforts to secu...

New data supports Furoscix ReadyFlow autoinjector for outpatient edema management in heart failure and CKD.
MannKind presented new clinical data at HFSA 2026 showing that Furoscix ReadyFlow, an autoinjector delivering subcutaneous furosemide, provides diuretic effects comparable to IV administration for treating edema in heart failure and chronic kidney di...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.